%0 Journal Article
%T Pharmacogenomic Approaches in Alzheimer's Disease: A Comprehensive Review
%A Ramdas Bhat
%A Varshini Varshini
%A Himasvi Himasvi
%A Ramakrishna Shabaraya
%J International Journal of Pharmaceutical And Phytopharmacological Research
%@ 2250-1029
%D 2023
%V 13
%N 4
%R 10.51847/qDMSgl63u7
%P 7-13
%X Alzheimer's disease (AD) stands as an intricate neurodegenerative condition impacting numerous individuals globally. In pursuit of enhancing the efficacy and safety of AD treatments, pharmacogenomic strategies have emerged. These methods encompass the identification of genetic variations influencing drug metabolism, the utilization of genetic testing to spot individuals vulnerable to AD, and the pinpointing of potential drug targets grounded in the genetic underpinnings of the ailment. As a demonstration, differences in the genetic variations present within the CYP2D6 gene can mold the processing of donepezil-an extensively employed cholinesterase inhibitor crucial in the treatment of AD. Identifying these genetic nuances can potentially facilitate personalized dosing or the exploration of alternative drugs. Correspondingly, genetic tests targeting the APOE gene can unmask individuals at a heightened risk of developing AD, enabling early interventions to deter or postpone the onset of the condition. Lastly, leveraging insights into the genetic origins of the disease, pharmaceuticals targeting the beta-amyloid protein, which accumulates in the brains of AD patients, are being crafted. Collectively, pharmacogenomic approaches harbor the potential to refine AD treatment by customizing therapy according to each individual's genetic blueprint. 
%U https://eijppr.com/article/pharmacogenomic-approaches-in-alzheimer39s-disease-a-comprehensive-review-gm2spwueizpmsxg